| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer
|
Sadahiro, Sotaro
|
|
2012
|
70 |
2 |
p. 285-291
|
article
|
| 2 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
|
Ku, Geoffrey Y.
|
|
2012
|
70 |
2 |
p. 231-238
|
article
|
| 3 |
Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in KrasG12D-LSL mice
|
Simmons, Brett H.
|
|
2012
|
70 |
2 |
p. 213-220
|
article
|
| 4 |
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
|
Yin, Ophelia Q. P.
|
|
2012
|
70 |
2 |
p. 345-350
|
article
|
| 5 |
DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080
|
Qiao, Foxiao
|
|
2012
|
70 |
2 |
p. 259-270
|
article
|
| 6 |
Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer
|
Tolcher, A. W.
|
|
2012
|
70 |
2 |
p. 305-313
|
article
|
| 7 |
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
|
Cho, Su-Hee
|
|
2012
|
70 |
2 |
p. 315-320
|
article
|
| 8 |
H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia
|
Matsuoka, Akihito
|
|
2012
|
70 |
2 |
p. 351-352
|
article
|
| 9 |
In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase
|
Sorscher, Eric J.
|
|
2012
|
70 |
2 |
p. 321-329
|
article
|
| 10 |
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
|
Yoshimoto, Masataka
|
|
2012
|
70 |
2 |
p. 331-338
|
article
|
| 11 |
Murine toxicology and pharmacokinetics evaluation of retinoic acid metabolism blocking agent (RAMBA), VN/12-1
|
Godbole, Abhijit M.
|
|
2012
|
70 |
2 |
p. 339-344
|
article
|
| 12 |
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
|
Kim, Young Hak
|
|
2012
|
70 |
2 |
p. 271-276
|
article
|
| 13 |
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
|
Strickler, John H.
|
|
2012
|
70 |
2 |
p. 251-258
|
article
|
| 14 |
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer
|
Mardjuadi, Feby
|
|
2012
|
70 |
2 |
p. 293-303
|
article
|
| 15 |
Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer
|
Sym, Sun Jin
|
|
2012
|
70 |
2 |
p. 277-284
|
article
|
| 16 |
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors
|
Trocóniz, Iñaki F.
|
|
2012
|
70 |
2 |
p. 239-250
|
article
|
| 17 |
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells
|
Bartscht, Tobias
|
|
2012
|
70 |
2 |
p. 221-230
|
article
|
Journal description